Shots:

• Asahi Kasei to receive an $20M up front- ~$210M as development & regulatory milestones and will be eligible for ~$180M milestones along with royalties on sales of the therapy.
• Lilly to acquire the exclusive rights for AK1780 while Asahi Kasei will retain the right to promote AK1780 in Japan and China (including Hong Kong and Macau)
• AK1780 is an orally bioavailable P2X7 receptor antagonist that has completed its P-I single and multiple ascending dose and clinical pharmacology studies for chronic pain conditions

 ­ Ref: PRNewswire | Image: Lilly